Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
Boehringer Ingelheim
McKinsey
Johnson and Johnson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LENVIMA

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Lenvima

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02430714 Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) Recruiting Eisai Co., Ltd. N/A 2015-05-01 This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.
NCT02579616 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Active, not recruiting Eisai Co., Ltd. Phase 2 2015-10-01 This is a multicenter, single arm, open-label study in participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent). This study contains 3 phases: a Pre-treatment phase that will last within 21 days; a Treatment phase that will consist of study treatment cycles and tumor assessment conducted every 6-8 weeks; and a Follow-up phase that will begin immediately after the Off-Treatment Visit and will continue as long as the participant is alive, unless the participant withdraws consent, or until the End of Study.
NCT02592356 Tyrosine Kinase Inhibitors (TKI) and Body Composition Recruiting M.D. Anderson Cancer Center N/A 2015-11-01 The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
NCT02640508 Eribulin and Lenvatinib in Advanced Solid Tumors Recruiting Eisai Inc. Phase 2 2016-05-01 The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
NCT02640508 Eribulin and Lenvatinib in Advanced Solid Tumors Recruiting Virginia G. Kaklamani Phase 2 2016-05-01 The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
NCT02657369 A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Recruiting Eisai Inc. Phase 2 2016-07-01 The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
NCT02702388 Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Sa Active, not recruiting Eisai Inc. Phase 2 2016-03-01 This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib other than the approved 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with RR-DTC with radiographic evidence of disease progression within the prior 12 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lenvima

Condition Name

Condition Name for Lenvima
Intervention Trials
Advanced Cancer 2
Cancer 2
Neoplasms 1
Malignant Neoplasm of Breast 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lenvima
Intervention Trials
Thyroid Neoplasms 4
Thyroid Diseases 3
Neoplasms 2
Endocrine Gland Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lenvima

Trials by Country

Trials by Country for Lenvima
Location Trials
United States 25
Japan 8
United Kingdom 7
France 6
Germany 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lenvima
Location Trials
Texas 4
California 3
Pennsylvania 2
Oregon 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lenvima

Clinical Trial Phase

Clinical Trial Phase for Lenvima
Clinical Trial Phase Trials
Phase 2 6
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lenvima
Clinical Trial Phase Trials
Recruiting 7
Active, not recruiting 2
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lenvima

Sponsor Name

Sponsor Name for Lenvima
Sponsor Trials
Eisai Inc. 5
Eisai Co., Ltd. 3
M.D. Anderson Cancer Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lenvima
Sponsor Trials
Industry 8
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Medtronic
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.